Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007.
暂无分享,去创建一个
[1] K. Rahbar,et al. Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[2] K. Rahbar,et al. Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Nicholas M. Donin,et al. Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer , 2018, The Journal of Nuclear Medicine.
[4] K. Rahbar,et al. Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[5] Uwe Haberkorn,et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[6] K. Rahbar,et al. Correlation of Intraprostatic Tumor Extent with 68Ga-PSMA Distribution in Patients with Prostate Cancer , 2016, The Journal of Nuclear Medicine.
[7] T. Holland-Letz,et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.